Nektar Therapeutics Charts Aggressive Path With REZPEG

Nektar Therapeutics ((NKTR)) has held its Q1 earnings call. Read on for the main highlights of the call.

Nektar Therapeutics’ latest earnings call struck an optimistic tone, as management highlighted strong mid-stage data for its lead asset REZPEG and a clear, accelerated road to Phase III in both atopic dermatitis and alopecia areata. Investors were reminded that while clinical and financing momentum is robust, the company still faces the familiar biotech trade-off of rising R&D spend, regulatory uncertainty and execution risk as it scales into global pivotal programs.

Durable Phase IIb Gains in Atopic Dermatitis

Management opened with Phase IIb REZOLVE-AD results showing that REZPEG’s efficacy not only persisted but deepened over a 36-week maintenance period in atopic dermatitis. Patients saw up to a fivefold increase in complete skin clearance rates, with sustained EASI-75 and EASI-90 responses and about 60% of those entering maintenance on EASI-75 or vIGA achieving IGA 0/1.

One-Year Alopecia Areata Data Strengthen the Case

In alopecia areata, the 52-week blinded extension of REZOLVE-AA showed new hair regrowth responses between weeks 36 and 52, with roughly 29% to 31% of patients on active drug reaching SALT-20 and no additional responders on placebo. The trial’s 94% completion rate over the 16-week extension and efficacy with twice-monthly dosing were framed as meeting the company’s target product profile.

ZENITH-AD Phase III Pivotal Program Taking Shape

For atopic dermatitis, Nektar plans to launch the ZENITH-AD Phase III program by July 2026, aiming for a first readout in mid-2028 and a biologics license filing in 2029. The design features three pivotal studies of about 510 patients each, including biologic-naive and biologic-experienced cohorts, with a 24-week induction followed by 28 weeks of maintenance to test monthly and quarterly dosing.

Blueprint for Alopecia Areata Registration

In alopecia areata, the company outlined a planned Phase III starting in early 2027 as a single, roughly 600-patient trial with a 52-week primary endpoint. The study would enroll patients aged 12 and older with baseline SALT scores of at least 50, and management cited regulatory precedent where one pivotal trial has been accepted in this indication.

Financing Bolsters a Billion-Dollar War Chest

Nektar underscored a transformed balance sheet after raising about $783 million in net proceeds since year-end, including a sizable April financing. The company ended the first quarter with $731.6 million in cash and investments, and now sits on more than $1 billion, giving it a projected cash runway into the third quarter of 2028 and an expected year-end 2026 balance of $800 million to $825 million.

Large Markets and Novel Mechanism Support Upside

Management emphasized the commercial appeal of REZPEG given more than 15 million U.S. moderate-to-severe atopic dermatitis patients, with fewer than one in ten currently on biologics, and roughly 6.7 million U.S. alopecia areata patients. They see a combined global market near $40 billion over five years and argue that a differentiated mechanism could expand biologic adoption beyond today’s niche penetration.

Safety Profile and Mechanism Aim to Compete with JAKs

REZPEG, which stimulates regulatory T cells, has so far shown a favorable safety profile and is positioned as suitable for chronic use without the boxed warnings and intensive monitoring associated with JAK inhibitors. The company also highlighted statistically significant improvements in comorbid asthma symptoms in atopic dermatitis patients, a benefit management says most rival therapies have not demonstrated.

Pipeline Progress and Academic Collaborations

Beyond REZPEG’s dermatology indications, Nektar pointed to its TrialNet-sponsored Phase II study in new-onset type 1 diabetes, with initial data expected in 2027. Preclinical work continues on TNFR2 agonist NKTR-0165 and bispecific NKTR-0166, with data presentations slated for the second half of 2026 and investigational new drug activity planned in 2027.

Revenue Base Remains Modest

On the income side, the company reported first-quarter noncash royalty revenue of $10.9 million and kept its full-year 2026 revenue guidance intact at $40 million to $45 million. The call made clear that near-term top line contributions remain limited and that the investment case rests heavily on future product approvals rather than current sales.

Losses and Operating Expenses Set to Climb

Nektar posted a first-quarter net loss of $44.9 million, or $1.82 per share, as it ramps investment in late-stage programs. Research and development expense was $35.7 million, with full-year R&D projected at $200 million to $250 million, while general and administrative costs were $13.4 million, with guidance of $60 million to $65 million as operating intensity increases.

Noncash Interest Adds to Reported Losses

Investors were reminded that noncash interest expense will be a recurring drag on reported earnings, totaling $7.9 million in the quarter and expected to reach $30 million to $35 million for the year. Management framed this charge as non-operational but acknowledged its impact on headline loss figures even as underlying cash outflows remain focused on development.

Regulatory Pathways Still Being Refined

While discussions with U.S. and European regulators for the atopic dermatitis Phase III program are largely complete, the path in alopecia areata remains less defined. The company is still working to clarify whether a single Phase III trial will suffice for approval and whether the label could eventually encompass moderate disease, with key end-of-Phase-II meetings yet to occur.

Global Trial Execution and Enrollment Challenges

The success of the ZENITH-AD program hinges on executing three large global trials, each with about 150 sites spread across North America, Europe and Asia-Pacific. Management acknowledged that site activation, contract research organization performance and cross-region enrollment rates could all become bottlenecks as the company ventures into more operationally complex Phase III territory.

Questions Around Durability and Dosing Strategy

Although on-treatment maintenance data in atopic dermatitis support monthly and quarterly dosing, the durability of responses after stopping therapy in both atopic dermatitis and alopecia areata remains an open question. Off-treatment observation data for alopecia areata are expected in late 2026 and for atopic dermatitis in early 2027, and those readouts may influence future registrational dosing strategies.

Cash Burn Trajectory Despite Strong Reserves

Despite its current billion-dollar cash position, Nektar forecast that it will finish 2026 with approximately $800 million to $825 million, highlighting the substantial planned burn required to fund multiple Phase III programs and pipeline initiatives. The company argued that this deliberate investment is necessary to capitalize on its clinical momentum and position REZPEG as a potential franchise asset across immune-mediated diseases.

Guidance Underscores Long Runway and Defined Milestones

Looking ahead, management reiterated guidance that its cash runway extends into the third quarter of 2028, with 2026 revenue still modest at $40 million to $45 million and R&D and G&A spending tracking in line with prior ranges. Key clinical milestones include the start of ZENITH-AD by mid-2026, the first Phase III data in 2028, a planned biologics filing in 2029, initiation of alopecia areata Phase III in early 2027 and initial TrialNet type 1 diabetes readouts in 2027.

Nektar’s earnings call painted the picture of a company leaning into a de-risked but still early asset, backing it with ample capital and a clear late-stage plan. For investors, the story now shifts from proof-of-concept to execution, with REZPEG’s differentiated profile and sizable markets offering meaningful upside, balanced against the inevitable costs and uncertainties of a global Phase III push.